Viridian Therapeutics (LTS:0K1R) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0K1R Viridian Therapeutics Inc LTS:0K1R
51 GF Score
Price $23.38
GF Value $1,352.73
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Viridian Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0K1R
51GF Score
Viridian Therapeutics Inc LTS:0K1R
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Viridian Therapeutics (LTS:0K1R) Overvalued in 2026?

Based on GuruFocus' analysis, Viridian Therapeutics stock appears to be undervalued. The current stock price of $23.38 is trading 98.3% below its estimated GF Value™ of $1,352.73. GuruFocus considers Viridian Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0K1R:

  • FFO:
  • GF Value™: $1,352.73 vs. price of $23.38 (98.3% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the LTS:0K1R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viridian Therapeutics Business Description

Other Exchanges VRDN:USA1S1:Germany
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
51GF Score

Get the complete analysis for LTS:0K1R

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.38
Price
$1,352.73
GF Value